» Authors » Cheryl N McMahill-Walraven

Cheryl N McMahill-Walraven

Explore the profile of Cheryl N McMahill-Walraven including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 644
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Layton J, Peetluk L, Wong H, Jiao Y, Djibo D, Bui C, et al.
Vaccine X . 2024 Feb; 16:100447. PMID: 38318230
Background: Monovalent booster/additional doses of COVID-19 vaccines were first authorized in August 2021 in the United States. We evaluated the real-world effectiveness of receipt of a monovalent booster/additional dose of...
12.
Djibo D, Margulis A, McMahill-Walraven C, Saltus C, Shuminski P, Kaye J, et al.
Pharmacoepidemiol Drug Saf . 2023 Sep; 33(1):e5690. PMID: 37669770
Purpose: To evaluate the positive predictive value (PPV) of an endometrial cancer case finding algorithm using International Classification of Disease 10th revision Clinical Modification (ICD-10-CM) diagnosis codes from US insurance...
13.
Harris D, Hayes K, Zullo A, Mor V, Chachlani P, Deng Y, et al.
JAMA Netw Open . 2023 Aug; 6(8):e2326852. PMID: 37531110
Importance: Head-to-head safety comparisons of the mRNA vaccines for SARS-CoV-2 are needed for decision making; however, current evidence generalizes poorly to older adults, lacks sufficient adjustment, and inadequately captures events...
14.
Hoffman S, Governor S, Daniels K, Seals R, Ziyadeh N, Wang F, et al.
Menopause . 2023 Jul; 30(8):824-830. PMID: 37449720
Objective: To assess the risk of select safety outcomes including endometrial cancer, endometrial hyperplasia, and breast cancer among women using conjugated estrogens/bazedoxifene (CE/BZA) as compared with estrogen/progestin combination hormone therapy...
15.
Davis J, McMahon P, Simon A, Haffenreffer K, Jamal-Allial A, McMahill-Walraven C, et al.
J Asthma . 2023 Jun; 60(12):2198-2206. PMID: 37347586
Asthma has a high healthcare burden globally, with up to 10% of the asthma population suffering from severe disease. Biologic agents are a newer class of asthma treatments for severe...
16.
Cocoros N, Gurwitz J, Cziraky M, Granger C, Harkins T, Haynes K, et al.
Clin Trials . 2023 Jun; 20(4):416-424. PMID: 37322894
Background: There are unique opportunities related to the design and conduct of pragmatic trials embedded in health insurance plans, which have longitudinal data on member/patient demographics, dates of coverage, and...
17.
Lo Re 3rd V, Dutcher S, Connolly J, Perez-Vilar S, Carbonari D, DeFor T, et al.
BMJ Med . 2023 Jun; 2(1):e000421. PMID: 37303490
Objective: To measure the 90 day risk of arterial thromboembolism and venous thromboembolism among patients diagnosed with covid-19 in the ambulatory (ie, outpatient, emergency department, or institutional) setting during periods...
18.
Hu M, Wong H, Feng Y, Lloyd P, Smith E, Amend K, et al.
JAMA Pediatr . 2023 May; 177(7):710-717. PMID: 37213095
Importance: Active monitoring of health outcomes after COVID-19 vaccination offers early detection of rare outcomes that may not be identified in prelicensure trials. Objective: To conduct near-real-time monitoring of health...
19.
Moll K, Lufkin B, Fingar K, Zhou C, Tworkoski E, Shi C, et al.
Vaccine . 2022 Nov; 41(2):333-353. PMID: 36404170
Background: The U.S. Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative conducts active surveillance of adverse events of special interest (AESI) after COVID-19 vaccination. Historical incidence rates...
20.
Hamad R, Lyman K, Lin F, Modrow M, Ozluk P, Azar K, et al.
BMC Public Health . 2022 Oct; 22(1):1882. PMID: 36217102
Background: It is increasingly recognized that policies have played a role in both alleviating and exacerbating the health and economic consequences of the COVID-19 pandemic. There has been limited systematic...